

Press Release

ProStrakan Group Announces New Chief Executive

Galashiels, UK. 7th July 2011 – ProStrakan Group plc, a subsidiary of Kyowa Hakko Kirin Co. Ltd. (KHK), and an international specialty pharmaceutical company, today announces that Dr Tom Stratford has been appointed as its new Chief Executive.

Tom will take over the role on 1st September 2011, at which point Peter Allen, who has been Acting Chief Executive since September 2010, will revert to his role as Non-Executive Chairman.

Currently Executive VP Business Development at ProStrakan, Tom (40) has worked with the company since 1997. His father, Harry Stratford, was a co-founder of the business in 1995 and retired as Chairman in 2007.

Commenting on Tom's appointment, Peter Allen, Chairman, said:

"I know I speak for the Board as a whole when I say that we are confident that in Tom Stratford we have the right person for the job. Tom's rounded experience, his excellent relationship-building skills and his exciting vision for the business going forward combine to ensure that he is an excellent leader for the business.

"This appointment ensures continuity for ProStrakan and underlines KHK's previously-stated intention for the business to be run as a standalone unit within the KHK group.

"I'm absolutely delighted for Tom and for ProStrakan and I am confident that this appointment will be a great success."

Dr Yuzuru Matsuda, Chief Executive Officer and President of KHK, said:

"I strongly support the decision of the ProStrakan Board to appoint Tom Stratford as CEO of ProStrakan and, on behalf of KHK I am delighted to convey our warmest congratulations on his appointment.

"I am confident that Tom's strong leadership skills and wealth of business experience in this industry will enable ProStrakan to further develop its business in Europe and the United States.

“I look forward to further growth of ProStrakan as a member of the KHK group and, as an important business partner for KHK, I underline our support for ProStrakan in the next stage in its development.”

Tom Stratford commented:

“I am very proud to have been given this opportunity to take ProStrakan to the next stage in its development. It is undoubtedly a very exciting time for everyone involved in the business across Europe and in the US.

“My ambition for the business is to build on ProStrakan’s proven successes in licensing, late stage development, registration and commercialisation of products and to continue to grow the business profitably.

“In KHK we have a supportive parent organisation with shared values. I look forward to helping ProStrakan to fulfil its promise as the springboard for KHK’s future success in Europe and the US as we bring KHK’s pipeline of innovative products to market.”

Ends

Enquiries:

ProStrakan
Callum Spreng,
Corporate Communications
+44 (0)1896 664000

Photographs:

Pics of Tom Stratford are available. Please call Callum Spreng or email:
callum.spreng@prostrakan.com

Notes to Editors:

Dr Tom Stratford

Career History

Feb 2008 - Present	ProStrakan PLC: <i>Executive VP Business Development</i>
Dec 2003 - Jan 2008	ProStrakan PLC: <i>Director Business Development</i>
May 2000 – Dec 2003	Strakan Pharmaceuticals: <i>Discovery Director</i>
Dec 1997 - April 2000	Strakan Pharmaceuticals: <i>Business Development Manager</i>
May 1994 – Nov 1994	Glaxo Group Research: <i>Lab Research Scientist</i>

Education

1990 – 1994 University of Bath, **Undergraduate**
BSc (Hons) Biochemistry, First Class

6 month research placements:

1992 Glaxo Group Research
1993 Tufts University, Boston

1994 - 1997 **Postgraduate, King's College, London**

1997 The Randall Institute, PhD (A Role for Retinoic Acid in the
Development of the Chick Limb)

About ProStrakan:

ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan is a subsidiary of Kyowa Hakko Kirin Co. Ltd., the Japan-based global specialty pharmaceutical company.

ProStrakan's head office is located in Galashiels in Scotland. The company's development capabilities are centered in Galashiels and Bedminster, New Jersey, USA. Sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, US, France, Germany, Spain, Italy and other EU countries.

You can learn more about the business at: www.prostrakan.com